PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Martorell, Claudia
TI  - Switching from RTV to COBI is Feasible in Patients with HIV-1 Who Have Mild-to-Moderate Renal Impairment
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 10--11
VI  - 14
IP  - 28
4099  - http://mdc.sagepub.com/content/14/28/10.short
4100  - http://mdc.sagepub.com/content/14/28/10.full
AB  - Cobicistat (COBI; approved as Tybost™ in the European Union and under review in the United States) is well tolerated in HIV-1 patients with mild-to-moderate renal impairment. The latest results build on prior phase 3 data demonstrating the long-term (144-week) noninferiority of COBI—which is eliminated mainly by liver metabolism, negating the need for dose adjustment in renal-impaired patients—to ritonavir as a protease inhibitor booster in treatment of HIV-1 infection in treatment-naïve patients.